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Cardiac Troponins in Dogs and Cats
R. Langhorn and J.L. Willesen
Cardiac troponins are sensitive and speciﬁc markers of myocardial injury. The troponin concentration can be thought of
as a quantitative measure of the degree of injury sustained by the heart, however, it provides no information on the cause of
injury or the mechanism of troponin release. Conventionally, the cardiac troponins have been used for diagnosis of acute
myocardial infarction in humans and have become the gold standard biomarkers for this indication. They have become
increasingly recognized as an objective measure of cardiomyocyte status in both cardiac and noncardiac disease, supplying
additional information to that provided by echocardiography and ECG. Injury to cardiomyocytes can occur through a vari-
ety of mechanisms with subsequent release of troponins. Independent of the underlying disease or the mechanism of troponin
release, the presence of myocardial injury is associated with an increased risk of death. As increasingly sensitive assays are
introduced, the frequent occurrence of myocardial injury is becoming apparent, and our understanding of its causes and
importance is constantly evolving. Presently troponins are valuable for detecting a subgroup of patients with higher risk of
death. Future research is needed to clarify whether troponins can serve as monitoring tools guiding treatment, whether
administering more aggressive treatment to patients with evidence of myocardial injury is beneﬁcial, and whether normalizing
of troponin concentrations in patients presenting with evidence of myocardial injury is associated with reduced risk of death.
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A biomarker is “a characteristic that is objectivelymeasured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharma-
cologic responses to a therapeutic intervention”.1 The
ﬁeld of cardiac biomarkers is continuously evolving. No
cardiac marker has yet gained its place in the general
veterinary biochemical proﬁle along with, for instance,
renal and hepatic biomarkers, and the status of the
heart is evaluated mainly through auscultation, ECG,
and echocardiography. However, the beneﬁt of applying
cardiac biomarkers in the clinical work-up of critically
ill patients (with or without heart disease as their pri-
mary diagnosis) is being explored and is showing pro-
mise. Among such promising biomarkers are the
cardiac troponins. The aim of this review is to describe
the current knowledge of cardiac troponins as diagnos-
tic and prognostic markers in dogs and cats compared
with that in humans.
Cardiomyocyte Physiology
The myocardial muscle cell is known as a cardiomy-
ocyte. Each cardiomyocyte consists of multiple myoﬁb-
rils arranged in parallel (Fig 1). A myoﬁbril consists of
a linear series of sarcomeres, the functional contractile
unit of the cell. A sarcomere contains two types of pro-
tein ﬁlaments. Thin actin ﬁlaments, each consisting of a
double helix of actin monomers, project from so-called
Z disks at the ends of the sarcomere. Thick myosin ﬁla-
ments cross-link at the sarcomere center from where
they interdigitate with the actin ﬁlaments. A myosin ﬁl-
ament contains a series of myosin molecules, each with
a helical tail and two globular heads.2–4 During muscle
contraction the many globular heads of a myosin ﬁla-
ment repetitively interact with actin in a cross-bridge
cycle, thereby pulling the thin ﬁlament along the thick
ﬁlament to shorten the sarcomere. During muscle relax-
ation the sites of actin and myosin interaction are steri-
cally blocked by the protein tropomyosin residing in the
actin helical groove and a ternary cardiac troponin pro-
tein complex located at regular intervals along the actin
ﬁlament.2–6 Troponin consists of 3 subunits which
together function as the molecular switch of cardiomy-
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ICU intensive care unit
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SIRS systemic inﬂammatory response syndrome
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ocyte contraction. Cardiac troponin T (cTnT), the tro-
pomyosin-binding subunit, secures the complex to the
thin ﬁlament. The additional subunits are responsible
for inhibition and promotion of contraction mediated
through calcium and ATP. In the absence of calcium,
cardiac troponin I (cTnI), the inhibitory subunit, inhi-
bits the hydrolysis of ATP necessary for actin and myo-
sin interaction. Calcium is the initiator of contraction,
removing the steric blockage of ﬁlament interaction
through binding to the calcium-binding subunit, cardiac
troponin C (cTnC).2,3,5,7,8
Troponin Characteristics
Troponin I and T subunits have tissue-speciﬁc iso-
forms for cardiac and skeletal (slow and fast-twitch)
muscle.9 For troponin C the cardiac isoform and one
skeletal isoform are completely homologous,9 making
the subunit unﬁt to be used as a cardiac marker. In the
remainder of the text the term cardiac troponins will,
therefore, refer only to cTnI and cTnT. Cardiac tro-
ponin T isoforms share more than 50% homology with
skeletal isoforms, but can be separately identiﬁed.10,11
Fetal cardiac isoforms are sometimes expressed in dis-
eased or injured skeletal muscle,12 however, and could,
in rare cases, compromise the cardiac speciﬁcity of
cTnT.13 Adult heart cTnT has a molecular weight of
37 kDa. Cardiac troponin I is a slightly smaller protein
of 24 kDa.9 It shares <50% homology with skeletal iso-
forms and contains a unique N-terminal peptide.10,11 It
is not expressed in skeletal muscle during disease states
and is, thus, uniquely cardiac.14–16 The full gene
sequence of cTnI in dogs and cats has been determined,
and the homology between canine/feline and human
cTnI genes is 95 and 96%.17
As the troponins are purely intracellular proteins,
their presence in circulation reﬂects intracellular content
release from cardiomyocytes.18 The majority of tro-
ponin in the cell is structurally bound in the contractile
apparatus and is sometimes referred to as the structural
pool, while a minor amount of free cytosolic troponin
makes up the so-called cytosolic pool (Fig 1). In
humans the cytosolic pool accounts for approximately
6–8% of cTnT19 and 3–4% of cTnI,20 whereas one
study comparing humans and dogs found 8% cytosolic
cTnT in humans, but only 2% in dogs.21 When destruc-
tion of a cardiomyocyte occurs, the cytosolic pool is
released quickly with a resultant early rise in circulating
troponin. This is followed by the slower release of the
structural pool as the contractile apparatus is broken
down, resulting in a sustained increase in circulating
troponin for days to weeks.19,20,22,23 It is believed that
the cytosolic pool alone can also be independently
released.22,24 A blood sample cannot be used to distin-
guish between the release of only cytosolic or both
cytosolic and structural troponin. Release kinetics are
complex as the time to peak concentrations and the size
of this increase depend on the cause and mechanism of
troponin release.22,25 However, after a cardiac insult, a
rise can be seen within 2–3 h,26 and peak concentration
is frequently reached in 18–24 h.23
Six pathobiological mechanisms are believed to be
responsible for cardiac troponin release either individu-
ally or in combination (Fig 2).16,27 Three mechanisms
refer to cell death with resultant release of both cytoso-
Fig 1. The contractile apparatus of a cardiomyocyte. Interaction of thin (actin) and thick (myosin) ﬁlaments is mediated by the troponin
complex (troponin I, T, and C) in the presence of calcium. The majority of troponin is structurally bound to the actin ﬁlament and its
associated protein tropomyosin. A small percentage is found free in the cytosol.
Fig 2. Possible mechanisms of troponin release from dying and
from viable cardiomyocytes.
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lic and structural troponin. Although troponin release is
well-described and always occurs with cell necrosis,28 it
is currently unknown whether troponin release does, in
fact, occur with cell apoptosis29–31 or with normal car-
diomyocyte turnover.32 Three other mechanisms
account for the release of only cytosolic troponin with-
out cell death. Troponin molecules can be subjected to
intracellular proteolysis with subsequent release of
degradation products small enough to pass through the
cell membrane.33 Increased membrane permeability has
also been documented in some disease states, resulting
in membrane gaps large enough to allow release of the
intact protein.34,35 Finally, it is possible that formation
and release of membranous vesicles containing cytosolic
troponin can occur from viable cells.22,36
Cardiac troponin I is released in several fold higher
concentrations than cTnT after a cardiac insult.8,37,38
This might reﬂect the smaller molecular size of cTnI,
but it has also been suggested that cTnT is more tightly
bound to the contractile apparatus.38,39 Accordingly,
presence of increased cTnT and cTnI concentrations
appears to reveal more severe cardiac injury than
increased cTnI alone.
The half-life of cTnI and cTnT in humans is approxi-
mately 2 h when only the cytosolic pool is released,
whereas a considerably longer half-life is seen with
release of the structural pool caused by a slow break-
down of the contractile apparatus.22,40 In the dog, the
half-life of free (experimentally injected, corresponding
to cytosolic) cTnI is 1.85 h,41 and release kinetics of
cTnT have also been found similar to those of
humans.21 Accordingly, release kinetics in dogs and cats
are assumed to mimic those of humans. In humans, car-
diac troponin is released as the complete ternary com-
plex, as free subunits, but predominantly as a complex
of cTnI-cTnC.42,43 Whether the same applies for dogs
and cats is currently unknown. Additionally, cTnI is
often released in a phosphorylated form,44 and tro-
ponins undergo proteolysis, oxidation, and reduction in
circulation resulting in a variety of diﬀerent circulating
peptides.19,43
The pathway of elimination of cardiac troponin has
not been clariﬁed. Because of its size it has been
thought to be eliminated through the reticulo-endothe-
lial system.45,46 However, renal clearance of smaller
degradation products might also be involved.47
Summing up the above, circulating cardiac troponins
have many characteristics of an ideal biomarker: car-
diac speciﬁcity, high sensitivity for injury (high myocar-
dial tissue content and early release after a cardiac
insult),10,22 negligible presence in circulation of healthy
individuals, a high dynamic range, persistence in circu-
lation for days post injury, and correlation with severity
of injury.8 Troponins are heart-speciﬁc, but it is impor-
tant to keep in mind that they are not disease-speciﬁc.
Accordingly, an increased troponin concentration
reﬂects myocardial injury irrespective of its cause.18
Another important fact is that troponins do not replace
advanced cardiac diagnostics (ie, echocardiography and
ECG) in evaluating the heart. Mild primary cardiac dis-
ease does not always result in cardiac injury, and exclu-
sion of cardiac disease should, therefore, only follow a
complete cardiac work-up.48,49
Measurement of Cardiac Troponins
The ﬁrst troponin assays were described in 1987
(cTnI)50 and 1989 (cTnT).51 The cTnT assay has only
been produced by a single manufacturer, and its sensi-
tivity has increased with newer generations of the assay,
the most recent being the 5th generation assay. It has
been speculated, however, that some of the assay’s
cross-species reactivity with animal cTnT might have
been lost in the process.52 The cTnT assay has not been
validated for use in dogs and cats, but numerous studies
exist in which the various generations of the assay have
been used in dogs with satisfactory results (Table 2).
Only one study has been published in which the cTnT
assay has been applied in cats.48 For cTnI, multiple
assays have been developed by a range of manufactur-
ers, and, accordingly, assays apply antibodies targeting
diﬀerent amino acid sequences.10 Consequently, results
are not easily comparable. Studies comparing diﬀerent
assays have found a reasonable correlation at low con-
centrations, but a considerable disagreement at high
concentrations.53 This disagreement could be due to the
release of a higher percentage of modiﬁed troponin pep-
tides in severe cardiac injury, with assays having vary-
ing ability to detect these forms.53 Two cTnI assays
have been validated for use in dogs and one in cats,
showing acceptable analytical and overlap perfor-
mance.54,55
In recent years increasingly sensitive assays have been
introduced, and the term “high-sensitivity” has often
been used indiscriminately to include all these assays
with a higher sensitivity than the so-called conventional
assays. With conventional assays troponin concentra-
tions in healthy individuals were below the detection
limit. This meant that the true upper reference limit
could not be determined and led to many studies assess-
ing the biomarker qualitatively, with patients classiﬁed
as “troponin positive” (detectable) and “troponin nega-
tive” (undetectable).56,57 With the sensitivity of current
assays, the actual concentrations of cardiac troponins in
healthy individuals are becoming apparent, and a quan-
titative interpretation of troponin concentrations is
strongly recommended as troponin concentrations cor-
relate well with both clinical disease severity58,59 and
with the degree of cardiac injury seen histopathologi-
cally.60–62 A deﬁnition of the term “high-sensitivity car-
diac troponin assay” has recently been published to
help navigate in the terminology.10 Applying the pub-
lished deﬁnition of the term “high-sensitivity”, it should
be reserved for assays that 1) have an imprecision below
10% at the 99th percentile of a healthy population and
2) are able to measure concentrations below the 99th
percentile, but above the detection limit in more than
50% (ideally more than 95%) of healthy individuals.
Recent studies using the Siemens ADVIA Centaur CP
TnI-ultra assay indicate that this assay might be a true
high-sensitivity assay in dogs and cats as it detected
cTnI in more than 95% of healthy dogs and cats exam-
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ined and had a low imprecision at both high and low
concentrations.48,55,63 The true upper reference limits
for dogs and cats (the 99th percentile of a large healthy
population) using this or any other assay have, how-
ever, not been reported.
Several factors can inﬂuence the results of cardiac
troponin analysis. Serum and plasma values are signiﬁ-
cantly correlated, but a tendency toward slightly lower
serum concentrations has been documented in dogs,54
whereas the opposite has been found in humans.54,64
Separate reference intervals might, therefore, be needed.
Troponin reportedly has long-term stability at 70 to
80°C,8,65 but is not stable at room temperature,54
refrigerator temperature,60 or 20°C.60 Short-term stor-
age (up to 24 h at 4°C and up to 3 months at 20°C)
before analysis might be acceptable according to studies
in alpacas and in cats.48,66 The eﬀect of freeze–thaw
cycles has varied with diﬀerent studies, but might also
aﬀect troponin concentrations.60 Interfering substances
in the blood such as seen with hemolysis, lipemia, ﬁb-
rin, increased alkaline phosphatase, rheumatoid factor,
heterophilic antibodies, or immune complexes can fal-
sely increase troponin concentrations.18,67 Circulating
troponin autoantibodies can cause negative interfer-
ence.68
Troponin T has not been measurable in healthy
dogs and cats in published studies. Reported cTnI
concentrations of healthy dogs and cats are shown in
Table 1.
Greyhounds and Boxers might have inherently higher
cTnI concentrations than other breeds.78,79 The minute
amounts of troponin present in circulation in healthy
individuals can likely be attributed to normal cardiomy-
ocyte turnover.18,80 In humans, male sex has been found
to be correlated with increased troponin concentra-
tion,81 but similar ﬁndings have not been reported in
dogs or cats. In humans,82 dogs,52,58,83 and cats,52 how-
ever, mildly increased concentrations have been docu-
mented in older individuals, possibly reﬂecting increased
myocardial remodeling with cardiomyocyte loss.18 Bio-
logical variation of both cTnI and cTnT should also be
taken into account when interpreting small increases in
seemingly healthy individuals.84,85 Finally, it is note-
worthy that extreme exercise can cause transient
myocardial injury in both humans and dogs.86–89
Primary Myocardial Injury
Acute Myocardial Infarction
Cardiac troponins are the biomarkers of choice for
diagnosis of acute myocardial infarction (AMI) in
humans.28,90 Atherosclerosis of the coronary arteries is
generally the underlying cause, and spontaneous rupture
of an atherosclerotic plaque leads to platelet aggrega-
tion, clotting, vessel stenosis or occlusion, ischemia, and
ultimately cardiomyocyte necrosis and myocardial
infarction.28,67 A diagnosis of AMI is made in the pres-
ence of a dynamic pattern in cardiac biomarker concen-
trations (preferably troponins) over 3–6 h with at least
one measurement above the upper reference limit (with
acceptable precision, that is, a coeﬃcient of variation
(CV) <10% at this cut-oﬀ) together with clinical, elec-
trocardiographic, or imaging ﬁndings consistent with
myocardial ischemia.28 Troponins can be regarded as
the clinical pathological correlate of myocardial lesions
as evidenced by histopathology, as the size of the
infarcted area correlates with cTnT concentration at
72 h postinfarction and with peak cTnI concentra-
tion.61,62 In parallel with the increase in circulating car-
diac troponin, a decrease in myocardial tissue troponin
content occurs, reﬂecting release of the myocardial con-
tractile apparatus.21,91 Interestingly, AMI occurs very
rarely in dogs and cats, most likely due to the infre-
quent occurrence of atherosclerosis in these species,92,93
and possibly to a well-developed coronary lateral circu-
lation62,94 which could provide a certain protection
against infarction.
There is an independent association between cardiac
troponin concentration and case fatality in AMI, and
risk stratiﬁcation according to level of troponin concen-
tration has revealed that even small elevations result in
an increased risk of death both short-term and long-
term.95–98 With the increasing use of high-sensitivity
assays, it has become apparent that even mild eleva-
tions, within the range undetected by conventional
assays, are associated with an increased risk of death.99
Therefore, cardiac troponins are prognostic markers not
only in patients with AMI, but also in patients with
stable coronary artery disease.
Cardiac Trauma
Cardiac trauma resulting from penetrating chest
trauma with cardiac involvement, blunt chest trauma
causing myocardial contusions, cardiac surgery,
catheterization procedures, or cardiopulmonary resusci-
Table 1. Reported cardiac troponin I (cTnI) concen-
trations from studies examining at least 20 healthy dogs
or cats.
Species n cTnI (ng/mL) Sample % screened
Dog 54 <0.05–0.12 EP 10069
41 <0.03–0.07 HP 2570
176 <0.02–0.15 HP 10071
24 <0.006–0.128 S 100*72
22 0.004–0.095 S 100*55
30 <0.006–0.136 S 10073
26 <0.1–0.17 S 10074
58 <0.01–0.05 EP 100*75
Cat 58 <0.05 EP 10069
21 <0.03–0.16 HP 2570
23 <0.003–0.09 S 100*48
20 0.004–0.091 S 100*55
37 <0.02–0.17 HP 10076
33 <0.03–0.16 HP 1677
cTnI, Cardiac troponin I; % screened, Percentage of dogs and
cats screened free of cardiac disease with echocardiography; EP,
EDTA plasma; HP, Heparin plasma; S, Serum.
*The study included hematological and biochemical proﬁles in
the health screening protocol.
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tation causes direct mechanical damage to the heart.100–
103 In the veterinary clinic, direct cardiac trauma occurs
frequently in conditions such as hit-by-car trauma,
high-rise syndrome, and thoracic bite injuries.38,104,105
The diagnosis of traumatic injury to the heart is impor-
tant as it can lead to cardiogenic shock, acute heart fail-
ure, life-threatening arrhythmias, or structural
damage.38,67 Troponin measurement is of value in
detecting or ruling out signiﬁcant blunt cardiac
injury.106
Primary Cardiac Disease
When evaluating cardiac disease, cardiac injury is not
limited to cases with overt myocardial ischemia, but is
also very common in those with primary structural car-
diac disease. Most human studies in this area have
focused on patients in heart failure regardless of cause,
whereas studies in dogs and cats have focused more on
the individual heart disease, revealing that increased
troponin concentrations occur in both congenital and
acquired heart diseases (Tables 2 and 3).
Longitudinal studies have revealed that humans as
well as animals with cardiac disease have chronically
increased troponin concentrations signifying ongoing
myocardial injury.30,48 Generally, although inﬂuenced
by the chosen assay, the concentrations of cardiac tro-
Table 2. Myocardial injury in cardiac and noncardiac diseases in dogs
Species Cardiac disease Noncardiac disease* cTnI measured cTnT measured
Dog SAS 71
PS 107
MMVD 49,58,71–74,108–111 109
DCM 49,71,75,83,108,112,113 112,114,115
ARVC 71,79,116
Myocarditis 117
Diroﬁlariasis 118–120 118
Cardiac hemangiosarcoma 121
Pericardial eﬀusion 39,49,122 39
Pancreatitis 52
Pyometra 123,124
Parvoviral enteritis 125,126
Leptospirosis 127
Leishmaniasis 128,129
Babesiosis 130,131 130
Erhlichiosis 132
Systemic inﬂammation 63 63
SIRS 133
Meningitis-arteritis 134,135
IMHA 136
Anemia 52
Neoplasia (mixed) 52,121,137 115
Lymphoma 52
Meningioma 138
Hemangiosarcoma 121
Respiratory disease 52,139
Brachycephalic syndrome 140
Hypoadrenocorticism 52
Hyperadrenocorticism 52
Snake envenomation 141–143 143
Heatstroke 144
GDV 145,146 146,147
cTnI, Cardiac troponin I; cTnT, Cardiac troponin T; SAS, Subaortic stenosis; PS, Pulmonic stenosis; MMVD, Myxomatous mitral valve
disease; DCM, Dilated cardiomyopathy; ARVC, Arrhythmogenic right ventricular cardiomyopathy; HCM, Hypertrophic cardiomyopathy;
IMHA, Immune-mediated hemolytic anemia; GDV, Gastric dilatation-volvulus; SIRS, Systemic inﬂammatory response syndrome.
*NB: Not all studies in the noncardiac disease group have ruled out primary cardiac disease as a cause of myocardial injury.
Table 3. Myocardial injury in cardiac and noncardiac
diseases in cats
Species
Cardiac
disease
Noncardiac
disease*
cTnI
measured
cTnT
measured
Cat HCM 48,77,148–150 48
Anemia 52,151
Neoplasia
(mixed)
52
Respiratory
disease
52,76,152
Hyperthyroidism 153,154
cTnI, Cardiac troponin I; cTnT, Cardiac troponin T, HCM:
Hypertrophic cardiomyopathy.
*NB: Not all studies in the noncardiac disease group have ruled
out primary cardiac disease as a cause of myocardial injury.
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ponins in primary cardiac disease are only mildly
increased (<1 ng/mL) in dogs and cats, and even in
those with severe congestive heart failure concentrations
rarely increase above 1–2 ng/mL.48,58,110 Nevertheless,
this limited, persistent, and often subclinical cardiac
injury seems to play a signiﬁcant role. Importantly,
unlike AMI in which dynamic changes in a patient’s
troponin concentrations can be used for a diagnostic
purpose, troponins have limited value in diagnosing pri-
mary heart diseases. This is not only true because non-
cardiac diseases can cause cardiac injury, but also
because an overlap between troponin concentration in
healthy individuals and those with cardiac disease has
been repeatedly shown.48,49,71 Those with only mild dis-
ease might not have any evidence of cardiac injury,
and, consequently, troponins should not be used to
either conﬁrm or exclude primary cardiac disease with-
out the simultaneous use of echocardiography and
ECG. They might, however, have a diagnostic purpose
in distinguishing between cardiac and noncardiac dysp-
nea in the emergency setting although conﬂicting evi-
dence exists with more promising results in
cats.76,139,152,155
The pathogenesis of myocardial injury in primary
structural heart disease is believed to be multifactorial,
resulting from complex interactions of mechanical,
neuro-humoral, inﬂammatory, and ischemic alterations
in the myocardium.67 These factors reﬂect underlying
disease (eg, coronary artery disease or sarcomeric gene
mutations associated with development of hypertrophic
cardiomyopathy (HCM)), initiating cause of injury (eg,
arrhythmia or treatment with cardiotoxic drugs), and
possible amplifying factors (eg, renal dysfunction).90
Speciﬁcally for HCM, mild chronic ischemia has often
been suggested as a cause, mediated through an oxygen
demand-supply mismatch due to the hypertrophied left
ventricle.156,157 An association between troponin con-
centration and left ventricular free wall thickness has
been reported in both humans and cats,77,148,158,159 but
a recent study failed to show an association between
changes in myocardial wall thickness and in troponin
concentrations over time.48 Ongoing myocardial injury
in HCM is, therefore, not simply explained by the
degree of hypertrophy. Table 4 lists known or suspected
factors initiating or contributing to myocardial injury in
structural cardiac disease.
Rather than simply being a result of cardiac disease,
myocardial injury itself might also be a possible cause
of disease progression.16 The gradual development of
heart failure is accompanied by cardiac remodeling as a
result of cardiomyocyte death, hypertrophy, and
replacement ﬁbrosis.111,158 As the remodeling pro-
gresses, a concurrent reduction in tissue content of tro-
ponin occurs.177 It has been hypothesized that
myocardial remodeling increases susceptibility to further
cardiac injury,18 and, in support of this, higher circulat-
ing troponin concentrations have been found in humans
as well as dogs with myocardial ﬁbrosis.111,158 There-
fore, the consequence of myocardial injury in cardiac
disease, independent of its causes and mechanisms, is
thought to be a worsening of cardiac function.16
In addition to structural heart disease, other diseases
directly involving the heart have been associated with
myocardial injury. These include inﬁltrative cardiac dis-
ease, cardiac neoplasia, inﬂammatory cardiac disease,
pericardial eﬀusion, and parasitic cardiac disease
(Table 2 lists those described in dogs).
Prognostic capacity of troponins has been detected in
humans with HCM,178 dilated cardiomyopathy
(DCM),179 and heart failure,180 cats with HCM,48,150
and dogs with myxomatous mitral valve disease
(MMVD),110,181 cardiomyopathies,71,75 and a combined
group of congenital and acquired heart diseases.59 Long
survival times are generally seen with low troponin con-
centrations, whereas even patients who are clinically
stable but have evidence of myocardial injury are at risk
of poorer outcome.182 Interestingly, not all human stud-
ies have found an association between degree of cardiac
injury and risk of death,180 and it is possible that pres-
ence rather than degree of injury is the actual prognos-
tic indicator. A recent study of cats with HCM,
however, found a prognostically signiﬁcant increase in
cTnT concentrations in nonsurvivors over the course of
the study.48 Similarly, a study in dogs with various
heart diseases revealed a signiﬁcantly higher risk of
death with increasing concentrations of cardiac tro-
ponins.59 Accordingly, the value of measuring cardiac
troponin longitudinally in the individual is a matter of
great interest. Research in humans with chronic heart
disease has indicated that for the individual patient an
increase over time could be associated with a higher risk
of death,182,183 and conversely, that outcome tends to
improve in patients with decreasing concentra-
tions.182,183 This is supported by a recent study in dogs
which showed a decrease in cTnI in dogs with severe
MMVD during the ﬁrst two weeks after initiation of
treatment.73 However, it has been reported in both
human and feline research that longitudinal changes in
troponin concentrations in a population only slightly
improve the discriminative power of the baseline mea-
surements for fatal outcomes.48,184 Thus, while longitu-
Table 4. Possible causes of myocardial injury in pri-
mary cardiac disease.
Initiating or contributing cause
Genetically abnormal myocyte function160,161
Ventricular hypertrophy (subendocardial ischemia)156,162
Fibrosis111,158
Hemodynamic overload (altered calcium-handling)33
Increased myocardial wall stretch34,163
Endothelial/microvascular dysfunction157,164
Activation of the renin–angiotensin–aldosterone system165
Activation of the sympathetic nervous system (norepinephrine
toxicity)30,166,167
Toxic eﬀects of inﬂammatory cytokines168,169
Oxidative stress170
Troponin autoimmunity171,172
Systemic hypotension46,173,174
Anemia175
Arrhythmia90,175,176
Inotropic drugs46,173,174
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dinal measurements might be of value in monitoring the
individual, it appears that a single measurement of car-
diac troponin at any time during disease progression
provides strong and independent prognostic informa-
tion.184
Secondary Myocardial Injury
Noncardiac Disease
Myocardial injury has been documented in a large
number of noncardiac diseases, most of them involving
critically ill patients, and especially those with inﬂam-
matory diseases and shock56,185–187 (Tables 2 and 3 lists
those described in dogs and cats). Many dogs and cats
have mildly increased cTnI concentrations (<1 ng/mL),
however, severe myocardial injury is rather common in
critically ill dogs and cats with noncardiac disease in
the experience of the authors (concentrations >10 ng/
mL are relatively common and even concentrations
>100 ng/mL have been reported in several
cases).63,143,146 Accordingly, most human studies and an
increasing number of veterinary studies focus on popu-
lations hospitalized in the intensive care unit (ICU). In
most human ICU patients increased troponin concen-
trations are found already at or within 24 h of admis-
sion,188,189 and a similar tendency has recently been
reported in dogs.190 This fact has led to speculation that
in-hospital complications follow rather than precede
development of myocardial injury.189 This supports a
theory of myocardial injury as a partial cause rather
than purely a result of the patient’s critical status.189
The pathogenesis of myocardial injury in noncardiac
disease is still being investigated, and possible causes
are listed in Table 5.
Overall, with the use of high-sensitivity assays,
myocardial injury has been detected in a large percent-
age of the critically ill.63,204 Importantly, those with and
without myocardial injury generally have similar clinical
characteristics.189,205 Measurement of cardiac troponin
is, therefore, necessary to discover the involvement of
myocardial injury in the individual’s critical status.125
Myocardial dysfunction is a serious complication of
critical disease, most frequently of sepsis, in both
humans and animals. It is characterized by ventricular
dilatation, hypocontractility, and diminished relax-
ation.56,206,207 Myocardial dysfunction is frequently
associated with troponin elevations,56,187,191,195whereas
it remains unclear whether the dysfunction results from,
accompanies, or causes myocardial injury.187,195
Myocardial dysfunction as visualized on echocardiogra-
phy is reversible with recovery from sepsis.208,209 This
argues against major cardiomyocyte death, and it is
believed that cardiomyocyte injury can thus also occur
reversibly with release of mainly the cytosolic troponin
pool.198 In human medicine, a necropsy case study of
deceased septic patients failed to show irreversible car-
diomyocyte necrosis in half of those that had increased
cardiac troponin concentrations antemortem,195 which
supports the theory of reversible cardiac injury in some
of these patients.
Cytokines are thought to play a very important role
in causing myocardial injury in inﬂammatory disease.
Increased troponin concentrations in critically ill
patients can be associated with signiﬁcantly higher
tumor necrosis factor-a (TNF-a) and interleukin- (IL-)
6 concentrations,56 and improvement of echocardio-
graphically visible myocardial dysfunction in one study
occurred in parallel with decreases in cTnI, TNF-a, IL-
8, and IL-10.210 Additionally, TNF-a and IL-1 cause
reduced cardiomyocyte contractility in in vitro stud-
ies.211 In critically ill dogs with systemic inﬂammation,
several cytokines, especially IL-10 and IL-15, are
thought to play a role in the events leading to myocar-
dial injury.63 The mechanism underlying cytokine-
mediated injury is believed to be a toxic eﬀect on the
cardiomyocyte membrane leading to increased perme-
ability.35,56 With resolution of this eﬀect, the injury
might be reversible.
Intoxication is another cause of increased troponin
concentrations. In dogs receiving doxorubicin, a directly
cardiotoxic drug, an increased troponin concentration is
the ﬁrst indicator of impending cardiac failure.137
Envenomation such as seen with snake bite is also a
cause of cardiac injury.141–143 Some venoms contain
directly cardiotoxic substances, but systemic inﬂamma-
tion induced by envenomation could also be a possible
cause of myocardial injury in these cases.141,142
Interestingly, critically ill patients with noncardiac
disease often have higher troponin concentrations than
patients with severe primary cardiac disease. The cause
of this has not been established, but it could be specu-
lated that systemic critical disease that aﬀects the heart
most likely aﬀects all cardiomyocytes, whereas primary
cardiac disease is more likely to chronically overburden
the heart, causing death of consecutive cells over time
as part of the ongoing remodeling process.
Even today the case fatality rate of the critically ill
(dogs and cats as well as humans) admitted to ICUs is
Table 5. Possible causes of myocardial injury in non-
cardiac critical disease.
Initiating or contributing cause
Hypotension186,188,189
Hypoxemia36,191
Anemia136,191,192
Fever193,194
Tachycardia188,191
Increased myocardial wall stress195,196
Arrhythmia188,189
Endothelial/microvascular dysfunction194,195,197
Microthrombosis198,199
Pulmonary thromboembolism200
Toxic eﬀects of endotoxin194,195,201
Toxic eﬀects of inﬂammatory cytokines35,56
Oxidative stress188,195
Epi- and endocardial hemorrhage130
Reperfusion injury associated with resuscitation procedures194,195
Inotropic/vasopressor drugs187,188,202
Cardiotoxic drugs (eg, doxorubicin)137
Envenomation (eg, snake venom)203
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high despite increasingly sophisticated diagnostic and
therapeutic management. Though, clinically, myocardial
injury is often unrecognized, its presence is associated
with prolonged morbidity and increased risk of death:
Humans and dogs with evidence of myocardial injury
have an up to 4 times higher case fatality rate than
those with normal troponin concentra-
tions,56,63,189,191,205 and increased troponins have also
been associated with prolonged ICU hospitaliza-
tion189,212 (only found in humans, likely because of
euthanasia of many dogs with poor prognosis). Cardiac
troponins have been shown to contribute independently
to established prognostic composite scores in both
humans and dogs.56,63,191 In dogs cTnI provided addi-
tional prognostic speciﬁcity to the Acute Patient Physio-
logic and Laboratory Evaluation (APPLE) score
without compromising its prognostic sensitivity.63 It
seems that myocardial injury, thus not accounted for by
the scores, supplies additional prognostic information
to already powerful prognostic scoring systems, a fact
that reveals the prognostic strength of the troponins
and identiﬁes a possible need for a general inclusion of
the status of the myocardium in patient evaluation and
prognostic scoring.197
Development of multiple organ dysfunction syndrome
(MODS) is a frequent complication and cause of death
in critical illness.213 Troponin is not a dysfunction mar-
ker, but it correlates well with echocardiographic evi-
dence of myocardial dysfunction56,187,191,195 and has
also been signiﬁcantly associated with other organ fail-
ure in human ICU patients.191 Inﬂammatory or hypoxic
stimuli that aﬀect the heart will likely aﬀect other
organs simultaneously. Thus, the association between
increased cardiac troponins and case fatality could be
attributable to an independent progression to MODS
occurring along with myocardial injury, but a myocar-
dial injury-related increased risk of MODS is also a
possibility if impaired organ perfusion follows dysfunc-
tion of the myocardium.191 Increased cardiac troponin
in critically ill individuals might, therefore, indicate a
critical state of a noncardiac condition, and troponin
has been referred to as a marker of multiorgan fail-
ure.214
In veterinary studies an association between cardiac
troponin concentrations and short-term case fatality has
been found in dogs with gastric dilatation volvulus
(GDV)145, parvoviral enteritis125, babesiosis130, systemic
inﬂammatory response syndrome (SIRS)133, and sys-
temic inﬂammation of any cause in dogs without pri-
mary structural cardiac disease.63 Two studies looked
into temporal changes of circulating troponin in hospi-
talized dogs, and these changes did not distinguish
short-term nonsurvivors from survivors.133,190 Larger
studies are necessary in order to examine the value of
serial troponin measurements in monitoring the individ-
ual.
It is still debated whether cardiac troponins have
prognostic signiﬁcance for long-term outcome. Some
studies have failed to show an association,215 whereas
other studies indicate that myocardial injury might be a
predictor of long-term negative outcome,196 perhaps
even being a partial cause of eventual clinical deteriora-
tion. In dogs, an association of admission (cTnT) and
peak (cTnI) troponin concentrations with 1-year case
fatality has been shown, although considerably weaker
than that with short-term case fatality.190 The study
suggested that cTnI was a better short-term predictor,
whereas cTnT appeared to predict long-term outcome
with greater certainty. Troponins might thus comple-
ment each other as prognostic markers. Because of the
possible association of long-term outcome with cardiac
troponin concentrations, critically ill individuals with
evidence of myocardial injury might have a need for
close follow-up after hospital discharge. Cardiac tro-
ponins could, therefore, play a role in identiﬁcation of
long-term risk patients (animals as well as humans) in
the ICU.
Renal Disease
Renal disease poses a dilemma for interpretation of
cardiac troponins because it is presently unknown
whether the markers are reliable when renal function is
compromised. Many human studies have shown an
increase in circulating cardiac troponins, especially
cTnT, in patients with renal disease.57,216 The troponin
detected is deﬁnitely of cardiac origin,90 but it is an
ongoing debate whether its rise is caused by a reduced
renal clearance, concurrent cardiac disease, or a delete-
rious eﬀect on the myocardium caused by uremic tox-
ins.27,216,217 Troponins have been considered too large
for renal elimination in total, but fragments of these
molecules also occur in circulation at a size that could
possibly be cleared by the kidneys.45,47 Interestingly,
cTnT is often increased in humans with renal insuﬃ-
ciency, whereas cTnI does not appear to be as fre-
quently aﬀected by renal disease.57,217,218 In dogs and
cats, however, two studies found frequent elevations of
cTnI in azotemic animals.219,220 These studies, unfortu-
nately, did not include echocardiographic examination
in their protocols, but one reported histopathological
ﬁndings of cardiac pathology in three of four necrop-
sies, suggesting a concurrent cardiac disease as a cause
of troponin release.219 A high risk of death or cardiac
events is known to exist in humans with end-stage renal
disease and increased concentrations of troponins,57,90 a
fact which further supports this theory. Importantly,
troponins have been shown to retain their prognostic
ability in humans even after adjustment for renal func-
tion,221 but, as a rule, it is still recommended to inter-
pret an increased troponin concentration cautiously in
the presence of renal disease.
Perspectives
Cardiac troponins are quantitative markers of
myocardial injury which can be reliably measured in
dogs and cats and which provide prognostic informa-
tion, seemingly irrespective of clinical presentation
(acute or chronic), suspected type of myocardial injury
(reversible or irreversible), and underlying disease (car-
diac or noncardiac). Clinically, the greatest strength of
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troponins can be summed up in their exceptional nega-
tive predictive value in both cardiac and noncardiac dis-
ease with low troponin concentrations generally
associated with improved chances of survival. Increased
concentrations, on the other hand, identify individuals
at increased risk of death.
In veterinary medicine, cTnI has generally been the
chosen marker. Cardiac troponin T is less sensitive than
cTnI, being released only with more severe cardiac
injury. As dogs and cats rarely develop AMI, and pri-
mary cardiac disease is often associated with low-grade
myocardial injury, cTnI became the obvious choice in
the initial studies of troponins in animals which
involved mainly this disease category. Today more sen-
sitive cTnT assays are available as well, and the marker
is becoming increasingly available for veterinary
research. Cardiac troponin I and cTnT might diﬀer
slightly in their prognostic potential, but overall the
two markers are highly correlated sources of similar
information, and clinically, it is considered suﬃcient to
measure one or the other.60 With the prognostic impor-
tance of even minimal myocardial injury, the authors
recommend cTnI as the cardiac injury marker of choice
in dogs and cats. Publication of upper reference limits
for relevant assays based on large healthy populations
is warranted for optimal use.
There are many possible causes of cardiac injury,
each of which leads to a rise in circulating cardiac tro-
ponins through one or more mechanisms of troponin
release. However, questions still in need of answering
include whether reversible and irreversible injury occur
as two separate entities in diﬀerent disease processes or
occur simultaneously; whether cardiac disease and non-
cardiac disease each might be most likely to cause either
reversible or irreversible injury; and whether one is
“worse” than the other from a prognostic point of view.
Shedding light on the pathophysiology behind myocar-
dial injury in renal disease is also crucial in order to be
able to apply the marker to all disease categories.
Researchers increasingly recommend using a multi-
marker approach in the evaluation and prognostication
of any patient.181 The combined potential of troponins
with markers of hemodynamic stress on the heart (eg,
natriuretic peptides), other markers of cardiomyocyte
injury (eg, fatty acid binding protein 3), and markers of
cardiac remodelling (eg, matrix metalloproteinases) is of
high importance in cardiology and requires further
research.18 In noncardiac disease, the contribution of
cardiac troponins to prognostic scoring systems shows
great promise, and it is believed that inclusion of tro-
ponins in future scores will have both clinical and
research beneﬁts. As assays hopefully become increas-
ingly available, and costs are reduced, it is also consid-
ered worthwhile to include measurements of cTnI
among the routine biochemical variables examined in
the clinical work-up of dogs and cats, just as biochemi-
cal variables reﬂecting renal and hepatic status are rou-
tinely measured.
Because of its possible reversible nature, it has been
discussed whether patients with evidence of myocardial
injury might beneﬁt from more aggressive treatment, in
which case normalizing of troponin concentrations
might be associated with an improved outcome.189,222
At this point in time, whether troponins are useful in
monitoring eﬀects of intervention, and whether adminis-
tering more aggressive treatment to individuals with evi-
dence of myocardial injury is beneﬁcial, are still
unanswered questions. Further studies, for example,
using troponins as surrogate endpoints for clinical tri-
als, are necessary to examine whether normalizing of
troponin concentrations in cases presenting with evi-
dence of myocardial injury is associated with improve-
ment in outcome.18 It is hoped that treatment strategies
will be developed which have the ability to reduce the
risk associated with myocardial injury.
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